FDA Warning Streak Continues, Underscoring Risky Products And Claims
This article was originally published in The Rose Sheet
Executive Summary
Agency has been turning up the heat this summer on skin-care marketers, posting two more July warning letters issued to companies for use of unapproved drug claims. Firms that sell anti-aging serums, eye-area formulas or anything promoted as an “anti-wrinkle” solution should review their claims to ensure compliance.
You may also be interested in...
FDA Warning Letters Target Skin Brighteners, Muscle-Relaxing Claims
Agency recently posted three warning letters issued to skin-care marketers in August for unapproved drug claims, including statements about reducing muscle contractions for anti-aging effects. All three warnings included a skin-brightening product among items identified as non-compliant on the basis of their claims.
FDA Warning Letter Barrage Continues With Five More To Close July
At least nine skin-care marketers received FDA warning letters in July for unapproved drug claims. In the month’s final two weeks, recipients included companies behind the Freeze 24-7 Instant Targeted Wrinkle Treatment and a Resurgent Stem Cell Firming Activator, among others.
FDA Not On Vacation: Warning Letter Burst Targets More Skin-Care Marketers
“Brightening” product claims continue to be flagged by FDA in warning letters, as well as statements about collagen production, cell regeneration and treatment of skin diseases. Medik8 marketer Ageless Aesthetics, Annemarie Gianni Skin Care and Be Green Bath & Body Founder Karen Roche are the latest warning recipients.